Trial reportHIV medicine2015
Pulmonary function in an international sample of HIV-positive, treatment-naïve adults with CD4 counts > 500 cells/μL: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.
Trial report in HIV medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 43 citations in OpenAlex.
- Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial.The Lancet. Respiratory medicine · 2016Trial
- Challenges, successes and patterns of enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.HIV medicine · 2015Trial
- The lung proteome in HIV-associated obstructive lung disease.ERJ open research · 2025Article
- Novel approach to exploring protease activity and targets in HIV-associated obstructive lung disease using combined proteomic-peptidomic analysis.Respiratory research · 2024Article
- Novel Approach to Exploring Protease Activity and Targets in HIV-associated Obstructive Lung Disease using Combined Proteomic-Peptidomic Analysis.Research square · 2024Article
- Pneumoproteins and biomarkers of inflammation and coagulation do not predict rapid lung function decline in people living with HIV.Scientific reports · 2023Article
- Spirometric reference equations for Cameroonians aged 4 to 89 years derived using lambda, mu, sigma (LMS) method.BMC pulmonary medicine · 2021Article
- Chronic obstructive pulmonary disease in HIV.Expert review of respiratory medicine · 2021Review
- Article
- Smoking and Accelerated Lung Function Decline in HIV-Positive Individuals: A Secondary Analysis of the START Pulmonary Substudy.Journal of acquired immune deficiency syndromes (1999) · 2018Article
- Adolescent age is an independent risk factor for abnormal spirometry among people living with HIV in Kenya.AIDS (London, England) · 2018Article
- Serious Non-AIDS Conditions in HIV: Benefit of Early ART.Current HIV/AIDS reports · 2018Review
- Pulmonary disease in HIV-infected adults in the era of antiretroviral therapy.AIDS (London, England) · 2018Review
- Article
- Plasma sphingolipids in HIV-associated chronic obstructive pulmonary disease.BMJ open respiratory research · 2017Article
- Non-infectious Pulmonary Diseases and HIV.Current HIV/AIDS reports · 2016Review
- Obstructive Lung Diseases in HIV: A Clinical Review and Identification of Key Future Research Needs.Seminars in respiratory and critical care medicine · 2016Review
- Maintaining lung health with longstanding HIV.Current opinion in infectious diseases · 2016Review
- Association of COPD With Risk for Pulmonary Infections Requiring Hospitalization in HIV-Infected Veterans.Journal of acquired immune deficiency syndromes (1999) · 2015Article
- Pathogenesis and management of emphysema in people with HIV.Expert review of respiratory medicineReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 8 institutions in 5 countries.
Funding
Abstract
objectivesThe aim of the study was to describe the prevalence and correlates of chronic obstructive pulmonary disease (COPD) in a multicentre international cohort of persons living with HIV (PLWH).
methodsWe performed a cross-sectional analysis of adult PLWH, naïve to HIV treatment, with baseline CD4 cell count > 500 cells/μL enrolled in the Pulmonary Substudy of the Strategic Timing of AntiRetroviral Treatment (START) trial. We collected standardized, quality-controlled spirometry. COPD was defined as forced expiratory volume in 1 s:forced vital capacity (FEV1 :FVC) ratio less than the lower limit of normal.
resultsAmong 1026 participants from 80 sites and 20 countries, the median age was 36 [interquartile range (IQR) 30, 44] years, 29% were female, and the median time since HIV diagnosis was 1.2 (IQR 0.4, 3.5) years. Baseline median CD4 cell count was 648 (IQR 583, 767) cells/μL, median viral load was 4.2 (IQR 3.5, 4.7) log10 HIV-1 RNA copies/mL, and 10% had a viral load ≤ 400 copies/mL despite lack of HIV treatment. Current/former/never smokers comprised 28%/11%/61% of the cohort, respectively. COPD was present in 6.8% of participants, and varied by age, smoking status and region. Forty-eight per cent of those with COPD reported lifelong nonsmoking. In multivariable regression, age and pack-years of smoking had the strongest associations with FEV1 :FVC ratio (P < 0.0001). There was a significant effect of region on FEV1 :FVC ratio (P = 0.010).
conclusionsOur data suggest that, among PLWH who were naïve to HIV treatment and had CD4 cell counts > 500 cells/μL, smoking and age were important factors related to COPD. Smoking cessation should remain a high global priority for clinical care and research in PLWH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.